Drug Risk-Adjusted Net Present Value
Access the risk-adjusted Net Present Value (NPV) of a specific drug.
Reveal a combination of analytics and proprietary data to deliver a complete picture of a drug’s current valuation based on revenue, R&D, likelihood of approval and sales-related costs.
This data will enable you to make better-informed decisions on the investment potential of a drug.
Included in these reports:
- Current investment value of a drug based on multiple factors, including LoA, revenue and sales-related costs
- Outlines key future events that could impact a drug’s NPV
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you.
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities.
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From refining strategy to fostering innovation, our insights power decisions for all corporate functions.
- Investment firms: From balancing risks to identifying alpha signals, our insights are widely used by investors and financial analysts.
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions.
- Other sectors: From media to academia, we work with sectors as diverse as our data.
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on:
- Unique data: Our proprietary data sources are unmatched and untapped, giving you exclusive insights to drive decisions.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge.
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them.
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform.
-
Product Insights
![]()
Net Present Value Model: Bayer AG's Elinzanetant
Empower your strategies with our Net Present Value Model: Bayer AG's Elinzanetant report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Leap Therapeutics Inc's Sirexatamab
Empower your strategies with our Net Present Value Model: Leap Therapeutics Inc's Sirexatamab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Johnson & Johnson's Gemcitabine
Empower your strategies with our Net Present Value Model: Johnson & Johnson's Gemcitabine report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Teva Pharmaceutical Industries Ltd's Golimumab Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Golimumab Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Eli Lilly and Co's Solbinsiran Sodium
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's Solbinsiran Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Crinetics Pharmaceuticals Inc's CRN-04894
Empower your strategies with our Net Present Value Model: Crinetics Pharmaceuticals Inc's CRN-04894 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Simcere Pharmaceutical Group Ltd's (borneol + edaravone)
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's (borneol + edaravone) report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Teva Pharmaceutical Industries Ltd's Omalizumab Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Omalizumab Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Teva Pharmaceutical Industries Ltd's Denosumab Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Denosumab Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
![]()
Net Present Value Model: Mind Medicine MindMed Inc's Lysergic Acid Diethylamide
Empower your strategies with our Net Present Value Model: Mind Medicine MindMed Inc's Lysergic Acid Diethylamide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.